Clinical Trials Sponsored by TxCell

Total 595 results

TxCell

Terminated

Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease (CATS29)

Crohn Disease

Austria, France, Belgium, United Kingdom, Germany, Italy
ENCell

Recruiting

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A

Charcot-Marie-Tooth Disease Type 1A

Korea, Republic of
ENCell

Completed

Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

Charcot-Marie-Tooth Disease, Type IA

Korea, Republic of
ENCell

Not yet recruiting

Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Korea, Republic of
ENCell

Completed

Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

Duchenne Muscular Dystrophy

Korea, Republic of
Micell Technologies

Completed

Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-II)

Coronary Artery Disease

New Zealand, Netherlands, United Kingdom, France, Belgium, Sweden
Shanghai IxCell Biotechnology Co., LTD

Not yet recruiting

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke

Ischemic Stroke
Micell Technologies

Completed

First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-I)

Coronary Artery Disease

Belgium, Australia, New Zealand
Axcella Health, Inc

Terminated

Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD

United Kingdom
Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD

United States
Axcella Health, Inc

Terminated

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

Hepatic Encephalopathy

Spain, United States, Canada, Italy, Hungary, Poland, United Kingdom
Axcella Health, Inc

Completed

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Sickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease | Sickle Cell Disorders

United States
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Axcella Health, Inc

Completed

Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

United Kingdom
Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Hepatic Insufficiency

United States
Exzell Pharma Inc.

Unknown

Efficacy of Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity

Non-Celiac Gluten Sensitivity

Canada
Vaxcell Bio, Co., Ltd.

Recruiting

Natural Killer (NK) Cell Therapy in Locally Advanced HCC

Locally Advanced Hepatocellular Carcinoma

Korea, Republic of
Excel-Tech Ltd.

Terminated

NeuroPath Comparative Validation Study Plan

Carpal Tunnel Syndrome (CTS)

United States
ECRI bv
Micell Technologies; Stentys

Completed

Study Comparing the MiStent SES Versus the XIENCE EES Stent (DESSOLVE III)

Coronary Stenosis

France, Germany, Netherlands, Poland
McMaster University
Axcella Health, Inc

Completed

Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization

Muscle Atrophy

Canada
Cell Genesys

Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Prostate Cancer
Cell Genesys

Completed

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)

Prostate Cancer
Cell Genesys

Completed

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer
Micell Technologies
Cardialysis BV; ClinLogix. LLC

Unknown

Trial of MiStent Compared to Xience in Japan (DESSOLVEJ)

Coronary (Artery); Disease

Japan
Cell Genesys

Terminated

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Prostate Cancer

United States, France, United Kingdom, Italy, Germany, Netherlands, Canada, Poland, Sweden, Belgium
Cell Genesys

Completed

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

United States
Cell Genesys

Terminated

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States
Cell Genesys

Terminated

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States, France, Belgium, Canada, United Kingdom, Sweden, Netherlands, Germany
Cell Genesys

Unknown

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Carcinoma, Transitional Cell | Bladder Neoplasms

United States, Canada
Cell Genesys

Completed

A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer
Cell Genesys

Completed

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Prostate Cancer

United States
Cell Genesys

Completed

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Multiple Myeloma

United States
Cell Genesys

Completed

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer | Nonresectable Pancreatic Cancer

United States
Cell Genesys

Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer

Prostate Cancer
CELL Technologies Inc.

Not yet recruiting

Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis (ACCELERATE3)

Musculoskeletal Diseases | Knee Osteoarthritis

Canada
Gamida Cell ltd

Completed

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Patients Transplanted With NiCord/CordIn (Omidubicel)

United States, Singapore, Spain, Netherlands
Gamida Cell ltd

Active, not recruiting

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Hematological Malignancies

United States
GC Cell Corporation

Completed

Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

Hepatocellular Carcinoma

Korea, Republic of
Gamida Cell ltd

Completed

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Hodgkin's Disease | Acute Myelogenous Leukemia (AML)

United States
Cell>Point LLC

Unknown

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

Coronary Artery Disease

United States
Cell>Point LLC

Active, not recruiting

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

Lung Cancer

United States
Cell Medica Ltd

Terminated

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC)

Lymphoma, Large B-Cell, Diffuse | Hodgkin Lymphoma | Post-transplant Lymphoproliferative Disorder

United States
Cell Medica Ltd

Terminated

Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT (EPROS)

Infectious Complications Following HSCT

United Kingdom
Living Cell Technologies

Completed

Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes

Argentina
iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
Bright Cell, Inc.

Not yet recruiting

Safety and Efficacy of YB-1113 in Treatment of POI

POI
R3 Stem Cell

Not yet recruiting

Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions

Stroke | Autoimmune Diseases | Kidney Diseases | Urologic Diseases | Renal Insufficiency | Arthritis | Renal Failure | Alzheimer Disease | Erectile Dysfunction | Cardiomyopathies | Pulmonary Disease | Neurologic Disorder | Orthopedic Disorder | COPD | Cardiac Event | CHF | Neuropathy;Peripheral
R3 Stem Cell

Not yet recruiting

Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions

Osteoarthritis | Degenerative Disc Disease | Pelvic Pain | Neuropathy | Degenerative Arthritis | Sports Injury | Ligament Injury | Tendinitis

United States
Brainstorm-Cell Therapeutics

Completed

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

Multiple Sclerosis, Chronic Progressive

United States

Clinical Trials Sponsored by TxCell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations